Published in J Neurooncol on April 04, 2014
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer (2008) 2.50
Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg (2006) 2.31
Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol (2012) 1.88
BRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants. J Neuropathol Exp Neurol (2012) 1.60
Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer (2008) 1.55
De-escalation of therapy for pediatric medulloblastoma: trade-offs between quality of life and survival. Pediatr Blood Cancer (2014) 1.39
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer (2009) 1.29
Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. Int J Radiat Oncol Biol Phys (2005) 1.24
A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours. Eur J Cancer (2009) 1.24
Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer (2007) 1.21
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology (2013) 1.14
Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol (2008) 1.14
A phase II study of metronomic oral topotecan for recurrent childhood brain tumors. Pediatr Blood Cancer (2011) 1.10
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol (2012) 1.10
Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. Cancer Res (2013) 1.10
Treatment of pediatric brain tumors. J Cell Physiol (2008) 1.09
Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis. Melanoma Res (2015) 1.06
Temozolomide in children with progressive low-grade glioma. Neuro Oncol (2007) 1.05
ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol (2010) 1.04
Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res (2002) 1.04
Cumulative incidence of radiation-induced cavernomas in long-term survivors of medulloblastoma. J Neurosurg (2006) 1.03
Cerebello-thalamo-cerebral connections in pediatric brain tumor patients: impact on working memory. Neuroimage (2011) 1.02
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis (2011) 1.02
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer (2013) 1.01
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol (2010) 1.00
Clinical and neuroanatomical predictors of cerebellar mutism syndrome. Neuro Oncol (2012) 0.99
Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer (2008) 0.99
Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. Neuro Oncol (2013) 0.98
High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors. Pediatr Blood Cancer (2004) 0.97
Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study. Cancer (2005) 0.96
Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology (2013) 0.96
Diagnostic sensitivity of serum and lumbar CSF bHCG in newly diagnosed CNS germinoma. Pediatr Blood Cancer (2012) 0.94
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol (2013) 0.90
Intracystic treatments for craniopharyngioma. Neurosurg Focus (2010) 0.90
Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro Oncol (2002) 0.89
A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma. Eur J Cancer (2010) 0.89
Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer (2008) 0.89
A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931). Int J Radiat Oncol Biol Phys (2009) 0.89
Novel Mutations in FA2H-Associated Neurodegeneration: An Underrecognized Condition? J Child Neurol (2012) 0.88
Identification of glutathione S-transferase (GST) polymorphisms in brain tumors and association with susceptibility to pediatric astrocytomas. J Neurooncol (2002) 0.87
EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study. Cancer (2015) 0.85
A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer (2005) 0.85
Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer (2005) 0.85
The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience. Childs Nerv Syst (2014) 0.84
Refining the staging evaluation of pineal region germinoma using neuroendoscopy and the presence of preoperative diabetes insipidus. Neuro Oncol (2004) 0.83
Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. Neuro Oncol (2003) 0.83
Genome-wide analysis of DNA copy number alterations and loss of heterozygosity in intracranial germ cell tumors. Pediatr Blood Cancer (2013) 0.82
Pleomorphic xanthoastrocytoma of the spinal cord: case report and literature review. Clin Neuropathol (2014) 0.82
Late spinal metastases from an isolated pineal region germinoma mimicking a schwannoma. J Clin Neurosci (2011) 0.82
Late mortality in pediatric patients with craniopharyngioma. J Neurooncol (2010) 0.81
Brainstem tumor presenting with tearing, photophobia, and torticollis. J AAPOS (2010) 0.81
Cochlear implantation following treatment for medulloblastoma. Laryngoscope (2010) 0.80
Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res (2005) 0.80
Brainstem corticospinal tract diffusion tensor imaging in patients with primary posterior fossa neoplasms stratified by tumor type: a study of association with motor weakness and outcome. Neurosurgery (2007) 0.80
Atypical teratoid rhabdoid tumors (ATRTs): the British Columbia's Children's Hospital's experience, 1986-2006. Brain Pathol (2012) 0.79
Malaysian siblings with friedreich ataxia and chorea: a novel deletion in the frataxin gene. Can J Neurol Sci (2004) 0.78
The development of Moyamoya syndrome after proton beam therapy. Pediatr Blood Cancer (2014) 0.78
Favorable-biology neuroblastoma presenting with leptomeningeal metastases?: a case presentation. J Pediatr Hematol Oncol (2004) 0.78
Potential role of ventricular tumor markers in CNS germ cell tumors. Pediatr Blood Cancer (2013) 0.78
Outcome of secondary high-grade glioma in children previously treated for a malignant condition: a study of the Canadian Pediatric Brain Tumour Consortium. Radiother Oncol (2006) 0.77
Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. Cancer Chemother Pharmacol (2003) 0.77
Long-term survival of children less than six years of age enrolled on the CCG-945 phase III trial for newly-diagnosed high-grade glioma: a report from the Children's Oncology Group. Pediatr Blood Cancer (2013) 0.77
Optic pathway gliomas in adolescence--time to challenge treatment choices? Neuro Oncol (2013) 0.77
Growing teratoma syndrome in intracranial non-germinomatous germ cell tumors (iNGGCTs): a risk for secondary malignant transformation—a report of two cases. Childs Nerv Syst (2014) 0.76
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. Childs Nerv Syst (2015) 0.75
Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer (2009) 0.75
Late effects in survivors of childhood CNS tumors treated on Head Start I and II protocols. Pediatr Blood Cancer (2014) 0.75
Noncarboplatin-induced Sensorineural Hearing Loss in a Patient With an Intracranial Nongerminomatous Germ Cell Tumor. J Pediatr Hematol Oncol (2016) 0.75
Occurrence of basal ganglia germ cell tumors without a mass. Arch Neurol (2009) 0.75
Intracranial tumors in infants: long-term functional outcome, survival, and its predictors. Childs Nerv Syst (2012) 0.75
MRI changes in the "normal" pineal gland following chemotherapy for suprasellar germ cell tumors. Pediatr Hematol Oncol (2008) 0.75